EC and FDA Approve Birch Triterpenes Gel for Epidermolysis Bullosa
What happened
Chiesi presented new scientific information and real-world experience regarding birch triterpenes topical gel at the 14th Annual Conference of the Pediatric Dermatology Research Alliance (PeDRA) on October 15, 2026. The gel was approved by the European Commission in June 2022 for treating partial-thickness wounds in patients with junctional and dystrophic epidermolysis bullosa (EB). The U.S. Food and Drug Administration (FDA) approved the same indication in December 2023.
From finanznachrichten.de
Why it matters
The approvals from the European Commission and the FDA validate the use of birch triterpenes topical gel for EB treatment. The presentation of new clinical evidence by Chiesi adds to the body of real-world scientific data for the therapy.
From finanznachrichten.de
Who's involved
- ChiesiPresented new scientific information on birch triterpenes topical gel.
- European CommissionApproved birch triterpenes gel for treating partial-thickness wounds in EB patients.
- FDAApproved birch triterpenes gel for treating partial-thickness wounds in EB patients.
Keep exploring
The entities involved
-
Chiesi
Nothing else this week.
-
European Commission
executive branch of the European Union
- FDA